COSCIENS Biopharma Inc. (CSCIF) stock
CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
$6.49+0.00 (0.00%)
Close on Oct 19, 2026Market cap $24.10MP/E –Yield –
COSCIENS Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
COSCIENS Biopharma's ebitda for the twelve months ending Mar 31, 2026 was -$6.59M. For fiscal 2025 it was -$9.49M. The highest annual figure on record is $9.90M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.49M | – |
| FY2024 | Dec 31, 2024 | -$16.67M | – |
| FY2023 | Dec 31, 2023 | -$3.19M | -155.0% |
| FY2022 | Dec 31, 2022 | $5.79M | – |
| FY2021 | Dec 31, 2021 | -$8.53M | – |
| FY2020 | Dec 31, 2020 | -$5.47M | – |
| FY2019 | Dec 31, 2019 | -$9.93M | -200.3% |
| FY2018 | Dec 31, 2018 | $9.90M | – |
| FY2017 | Dec 31, 2017 | -$22.98M | – |
| FY2016 | Dec 31, 2016 | -$29.28M | – |
| FY2015 | Dec 31, 2015 | -$34.61M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$389.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.81M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.68M | -109.9% |
| Q3 FY2023 | Sep 30, 2023 | -$748.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$752.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.17M | – |
| Q4 FY2022 | Dec 31, 2022 | $16.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.68M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.09M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.29M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.40M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.17M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.70M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.69M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.66M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.87M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.03M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.00M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.48M | – |
See a number that looks wrong?